News
Health Canada approves Rybelsus to treat type 2 diabetes.- Novo Nordisk
Health Canada has approved Rybelsus (semaglutide tablets) from Novo Nordisk as a treatment option to improve glycemic control in adults with type 2 diabetes mellitus, along with diet and exercise. Rybelsus is the first and only glucagon-like peptide-1 (GLP-1) analogue available in a tablet and is indicated as a monotherapy when metformin is considered inappropriate due to intolerance or contraindications.
Rybelsus can be used in combination with other medicinal products for the treatment of type 2 diabetes in adults. Rybelsus will be available in pharmacies across Canada beginning April 27, 2020.
Condition: Diabetes Type 2
Type: drug
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins